Researchers discover ancient predatory, fanged fish that swam in Nova Scotia waters
HALIFAX — Researchers have discovered a new species of ancient fish with hooked front fangs that made them a fearsome and effective predator.
A paper published in the Journal of Vertebrate Paleontology this week says the long, curved jaw of the animal sheds light on how fish were evolving smaller, front teeth that acted like fishing hooks, about 350 million years ago.
Meanwhile, the centimetre-long back fangs were used to chew the catch before digestion into a body that may have been almost a metre long. They hunted for prey in the inland waters of Nova Scotia, in what was likely a vast inland lake.
Lead author Conrad Wilson, a doctoral candidate in paleontology at Carleton University, said in an interview Friday that the fish has been named Sphyragnathus tyche, with the first phrase meaning "hammer jaw."
"I would say it's a fairly fearsome looking fish. If its mouth is open, you would see those fangs in the jaw," he said.
But the fossil is also significant for the clues it offers to the evolution of ray-finned fish — a huge and diverse vertebrate group that occupies a wide range of aquatic and semi-aquatic environments around the globe.
"These fish were the last major group of vertebrates to be identified and we still have big gaps in our knowledge about their early evolution," said the researcher, who published his paper with Chris Mansky, a fossil researcher at the Blue Beach Fossil Museum in Hantsport, N.S., and Jason Anderson, a professor of anatomy at the veterinary faculty at the University of Calgary.
"The fossils are telling us about what the fish existing right after a mass extinction looked like," said Wilson, referring to the transition from the Devonian to the Carboniferous periods.
Wilson says paleontologists have wondered how ray-finned fish recovered from the extinction period as other groups of fish, such as the heavily armed category referred to as placoderms, were disappearing.
"The beach where this fossil was discovered tells us is ... this is a group of animals that is doing well, pretty quickly, after a mass extinction," he said.
The paper theorizes that the feeding methods of the evolving teeth may have played a role, creating an evolutionary advantage for the species.
Wilson noted "that particular feature of the curved and pointy fang at the front and processing fangs at the back became a feature of many species in times to come."
The area where the fossil was found — at Blue Beach on the Minas Basin, about 90 kilometres north of Halifax — was believed to be part of a vast freshwater lake not far from the ocean.
The research team's paper credits Sonja Wood, former director of the Blue Beach Fossil Museum, for finding the fossilized jaw by urging Mansky to check along a creek that flowed onto the beach.
Wood, who died last year, was in a wheelchair and had urged her colleague to search the area. "She had a good feeling about what could be found ... and she said he should go and have a look," said Wilson.
"He went down and sure enough it (the jaw fossil) was sitting right there," said the researcher, adding that Mansky managed to recover the fossil before a storm rolled through that night.
Wilson said more discoveries are possible as examination of the fossils from the Blue Beach area continues.
"We have lots of different anatomies that simply haven't been described yet. And we'll be working on that in a paper that's coming up in a few months," he said.
This report by The Canadian Press was first published June 21, 2025.
Michael Tutton, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
3 hours ago
- Bloomberg
Data-Center Limits Will Hurt AI Boom, Alberta First Nations Say
Indigenous communities in Canada's Alberta province are pushing back on restrictions they say hinder investment in new data centers needed to power the growth of artificial intelligence. The Enoch Cree, Alexis Nakota Sioux, Alexander and Paul First Nations sent a letter to the province's premier, Danielle Smith, saying recently announced limits on data-center access to the power grid will undermine their communities' efforts to generate revenue from the AI boom.


Medscape
4 hours ago
- Medscape
Guselkumab Clears Scalp Psoriasis Across Skin Tones
TOPLINE: In the VISIBLE trial, guselkumab led to significant and sustained improvements in scalp psoriasis severity and quality of life in patients with skin of color through 48 weeks. METHODOLOGY: Researchers evaluated outcomes in a cohort of patients in the phase 3b randomized VISIBLE trial, which included 102 adults with skin of color and scalp psoriasis (mean age, 42.5 years; Fitzpatrick skin type IV-VI, 62.7%; 56.9% men) at 45 sites in the US and Canada from September 2022 to June 2024. Participants self-identified as Asian (38.2%), non-White Hispanic or Latino (38.2%), Black (10.8%), and Middle Eastern (4.9%). Participants were randomly assigned 3:1 to receive guselkumab or placebo with crossover to guselkumab at week 16. Coprimary endpoints were scalp-specific Investigator's Global Assessment (ss-IGA) score of 0/1 and 90% improvement in Psoriasis Scalp Severity Index (PSSI) at week 16. Secondary outcomes were changes in PSSI, scalp surface area, Dermatology Life Quality Index (DLQI), Scalp Itch Numeric Rating Scale, Psoriasis Symptoms and Signs Diary, and complete clearance. TAKEAWAY: At week 16, patients treated with guselkumab showed significantly higher response rates than those with placebo for ss-IGA 0/1 (68.4% vs 11.5%; P < .001) and PSSI 90 (65.8% vs 3.8%; P < .001). Complete scalp clearance was higher in the guselkumab group: ss-IGA 0 (57.9% vs 3.8%; P < .001) and PSSI 100 (59.2% vs 3.8%; P < .001). At week 16, guselkumab led to greater mean percentage improvements in PSSI (least squares mean [LSM] change, 87.6% vs 37.8%; P < .001) and scalp surface area (SSA; LSM change, 86.6% vs 33.4%; P < .001). Patients reported improved quality of life (DLQI: LSM change, -9.7 vs -2.2; P < .001), symptom relief (LSM change, -44.8 vs -8.3; P < .001), and improvements in itch scores (69.4% vs 24.0%; P < .001) with guselkumab vs placebo at week 16. Over 90% of patients achieved mean percentage improvements with guselkumab in PSSI and SSA by week 48, with 67.1% achieving complete scalp clearance (ss-IGA 0). One patient in the placebo group experienced at least one serious adverse event (SAE) at week 16 vs none in the guselkumab-treated group. From 0-48 weeks, at least one SAE was reported in 2.5% of patients on guselkumab; no adverse events resulted in drug discontinuation. IN PRACTICE: The findings showed that 'guselkumab is highly effective for the treatment of moderate-to-severe scalp psoriasis in individuals with skin of color across the spectrum of objectively measured skin tones,' the study authors concluded. SOURCE: This study was led by Amy McMichael, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and was published online on June 25 in JAMA Dermatology. LIMITATIONS: Postinflammatory pigment alteration, a common concern in people with skin of color, was not fully captured. DISCLOSURES: Johnson & Johnson provided funding support for this study. McMichael reported receiving personal fees, nonfinancial support, and royalties from various organizations, including Johnson & Johnson. Several other authors also reported receiving personal fees, investigator fees, salary, stock, and stock options from Johnson & Johnson and multiple other companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
6 hours ago
- Yahoo
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre ('DRDC'), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by September 2025. With continued promising ongoing results and current DRDC and regulatory initiatives, there are potential pathways for Health Canada to grant faster approval for DRDC strategic stockpiling plans for treating nerve agent or organophosphate pesticide poisoning in 2026. In addition, plans are being pursued to explore the use of Bucillamine in traumatic brain injury (TBI) from concussive/explosive forces and viral infections. In light of current world events, therapeutic options for the battlefield are becoming a high priority for nations involved. Bucillamine has the potential to become a vital option for medical countermeasures and in the battlefield. Bucillamine: A Promising Medical Countermeasure Bucillamine is a thiol-based drug with a well-established safety profile and strong anti-inflammatory and antioxidant properties. Its mechanism of action is believed to protect the brain and other organs by replenishing glutathione, the body's master antioxidant, which is depleted during toxic exposures. This unique property makes Bucillamine a compelling candidate for both preventing and treating the debilitating, long-term neurological damage caused by nerve agents. Its potential applications include: Prophylactic (Pre-Exposure) Use: Administering to military personnel and first responders before potential exposure to a nerve agent threat. Post-Exposure Treatment: Mitigating the severe brain injury and other organ damage that occurs following an attack, complementing existing therapies. Urgent Global Need and Substantial Market Opportunity The threat of chemical weapons, specifically nerve agents, remains a deep concern for governments worldwide. In today's heightened geopolitical climate, the need for effective medical countermeasures is more critical than ever. Ongoing conflicts, such as those in Ukraine and the Middle East, have placed a renewed focus on soldier survivability and readiness. Bucillamine's potential to be administered easily on the battlefield could be a game-changer, protecting armed forces from chemical threats and the neurological effects of blast-induced TBI. Government Stockpiling: A Proven and Lucrative Market Western governments have well-established programs for stockpiling medical countermeasures to protect their military and civilian populations. Examples include: The U.S. Project BioShield Act: This program, managed by agencies like the Biomedical Advanced Research and Development Authority (BARDA), allocates billions of dollars to procure life-saving treatments for chemical, biological, radiological, and nuclear (CBRN) threats. Pandemic Preparedness: The recent global response to COVID-19 demonstrated the massive scale at which governments will procure and stockpile vaccines and therapeutics to ensure national security and public health. Successful approval for Bucillamine as a nerve agent countermeasure would position Revive to pursue significant and lucrative procurement contracts with the Canadian government and its "Five Eyes" intelligence partners (U.S., U.K., Australia, New Zealand), representing a massive market opportunity. 'Our collaboration with DRDC is reaching a critical milestone at a time when the world is acutely aware of the need for robust national defense and preparedness,' said Michael Frank, CEO of Revive Therapeutics. 'In a world of increasing geopolitical instability, an effective and easily administered countermeasure like Bucillamine has the potential to protect our service members and first responders. The successful conclusion of this study could unlock a substantial commercial opportunity through government stockpiling contracts and firmly establish Revive as a key player in the medical countermeasure space.' A Compelling Investment Proposition Revive Therapeutics offers a unique investment opportunity based on the significant potential of Bucillamine: High-Profile Government Partnership: Collaboration with the Canadian Department of National Defence lends significant credibility and a clear path to market. Urgent, High-Value Market: The global nerve agent countermeasure market is driven by non-negotiable government defense spending. Expedited Regulatory Pathway: Potential for accelerated approval and stockpiling initiatives in 2026. Pipeline Expansion: Proven success in this indication could support and fund further development for TBI and viral infections. The Company will continue to provide updates on its progress with the DRDC study as it nears completion. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics 1 888 901 0036Email: mfrank@ Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'may', 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company's cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading 'Risk Factors' in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data